Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents

Costa, Michelle F.; Said, Nuha R.; Zimmermann, Bernard

doi:10.1016/j.semarthrit.2007.08.003

Cited by 215 publications

(206 citation statements)

References 29 publications

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…In another study over 50% of infliximab-treated patients and 10% of etanercept-treated patients developed anti-dsDNA antibodies, suggesting differences in immunogenicity between the drugs 4 . This observation is of interest in view of the data reported in another study of anti-TNF-induced lupus that shows infliximab is associated with anti-TNF-induced lupus more frequently than etanercept or adalimumab 5 .…”

Section: Patientmentioning

confidence: 72%

See 1 more Smart Citation

Successful Switch of Patients with Rheumatoid Arthritis Developing Anti-tumor Necrosis Factor (anti-TNF)-induced Lupus to Another Anti-TNF Agent

Ye¹,

Sholter²,

Martin³

et al. 2011

J Rheumatol

View full text Add to dashboard Cite

Section: Patientmentioning

confidence: 72%

“…Affected patients have also been reported to have renal involvement, an uncommon finding in classic drug-induced lupus 5 .…”

Section: Patientmentioning

confidence: 99%

Successful Switch of Patients with Rheumatoid Arthritis Developing Anti-tumor Necrosis Factor (anti-TNF)-induced Lupus to Another Anti-TNF Agent

Ye¹,

Sholter²,

Martin³

et al. 2011

J Rheumatol

View full text Add to dashboard Cite

“…According to the acute-type histological damage observed in the kidney of the present case, it is unlikely that the long time use of IFX induced ATIN. We readministered IFX, because 25-50% of the reported cases of TNF-α inhibitors-associated autoimmune diseases could be rechallenged with the offending drugs without either a recurrence or worsening of symptoms (1,3,12). The low dose rechallenge of IFX did not induce renal impairment.…”

Section: Discussionmentioning

confidence: 99%

Acute Tubulointerstitial Nephritis Associated with Infliximab in a Patient with Crohn's Disease

Iwai

Imai

et al. 2016

Intern. Med.

View full text Add to dashboard Cite

We report the findings of a 46-year-old man, who presented with fever and renal dysfunction while undergoing treatment for Crohn's disease with infliximab (IFX). Remittent fever and renal dysfunction with urinary casts developed and lasted for 3 weeks without deterioration of Crohn's disease. Renal biopsy revealed acute tubulointerstitial nephritis (ATIN). After the discontinuation of IFX, his fever and renal abnormalities resolved. We herein report the first known case of ATIN associated with IFX.

show abstract

“…The limited findings presented herein seem to indicate that TNF antagonists may increase levels of autoantibodies in SLE patients, but this increase is not associated with worsening clinical disease. Further study will be necessary to determine the efficacy of TNF antagonists in cutaneous disease and to clarify the significance of treatment-associated autoantibody increases in SLE patients [19,20,21]. …”

Section: -Lupus Erythematosusmentioning

confidence: 99%

Off-Label Dermatological Uses of Etanercept Treatment

2016

J turk acad dermatol

View full text Add to dashboard Cite

Background: Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine that plays an immunomodulatory role in a variety of systemic and dermatologic disease. Its blockade can be achieved by using specific inhibitors like etanercept. At present, etanercept is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and psoriasis treatment. However, it has been used with promising results in other inflammatory dermatoses. Etanercept treatment have been reported in the following dermatologic diseases: sarcoidosis, hidradenitis suppurativa, acne vulgaris, cicatricial pemphigoid, pemphigus vulgaris, Hailey-Hailey disease, Behçet' s disease, oral aphthous stomatitis, pyoderma gangrenosum, multicentric reticulohistiocytosis, apthous stomatitis, Sneddon-Wilkinson disease, acrodermatitis continua of Hallopeau, SAPHO syndrome, pityriasis rubra pilaris, vitiligo, necrobiosis lipoidica, silicone granulomas, Sweet's syndrome, atopic dermatitis, dyshidrotic eczema, toxic epidermal necrolysis, alopecia areata, centrifugal annular erythema, primary amyloidosis, erythroderma-related pruritus in Sézary syndrome, cutaneous T-cell lymphoma, inflammatory linear verrucous epidermal nevus, excessive scarring, postherpetic neuralgia, dermatomyositis, vasculitis, lupus erythematosus, and scleroderma. The vast majority of these reports are in the form of individual case reports and small case series. A growing number of published reports suggest that etanercept treatment may be effective in the treatment of numerous inflammatory skin disease outside their currently approved indications.

show abstract

Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents

Cited by 215 publications

References 29 publications

Successful Switch of Patients with Rheumatoid Arthritis Developing Anti-tumor Necrosis Factor (anti-TNF)-induced Lupus to Another Anti-TNF Agent

Successful Switch of Patients with Rheumatoid Arthritis Developing Anti-tumor Necrosis Factor (anti-TNF)-induced Lupus to Another Anti-TNF Agent

Acute Tubulointerstitial Nephritis Associated with Infliximab in a Patient with Crohn's Disease

Off-Label Dermatological Uses of Etanercept Treatment

Contact Info

Product

Resources

About